^
    Back
    Association details:
    Biomarker:KMT2A rearrangement
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:PRT2527 (CDK9 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2022
    Title:

    210 PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

    Published date:
    11/03/2022
    Excerpt:
    PRT2527 administration resulted in a significant (p<0.01) improvement in median survival in the aggressive KMT2A-rearranged primary systemic B-ALL model.
    DOI:
    https://doi.org/10.1182/blood-2022-158998